Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
F 28.59 -2.99% -0.88
KURA closed down 2.99 percent on Friday, April 16, 2021, on 49 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical KURA trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
200 DMA Resistance Bearish -2.99%
50 DMA Resistance Bearish -2.99%
Bollinger Band Squeeze Range Contraction -2.99%
Multiple of Ten Bearish Other -2.99%
200 DMA Resistance Bearish -2.09%
Crossed Above 20 DMA Bullish -2.09%
Bollinger Band Squeeze Range Contraction -2.09%
Older End-of-Day Signals for KURA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kura Oncology, Inc. Description

Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Oncology Cancers Lymphoma Thyroid Carcinoma Backup H Drive Signal Transduction Cell Signaling Oncogenes Protein Kinase Acute Leukemia Kras Leukemias Benzamides Blood Cancers Ras Subfamily

Is KURA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 43.0
52 Week Low 9.8875
Average Volume 751,682
200-Day Moving Average 29.55
50-Day Moving Average 29.91
20-Day Moving Average 27.97
10-Day Moving Average 28.82
Average True Range 1.81
ADX 21.01
+DI 15.26
-DI 20.99
Chandelier Exit (Long, 3 ATRs ) 24.94
Chandelier Exit (Short, 3 ATRs ) 29.52
Upper Bollinger Band 30.52
Lower Bollinger Band 25.42
Percent B (%b) 0.62
BandWidth 18.22
MACD Line -0.16
MACD Signal Line -0.40
MACD Histogram 0.2415
Fundamentals Value
Market Cap 1.62 Billion
Num Shares 56.7 Million
EPS -1.57
Price-to-Earnings (P/E) Ratio -18.23
Price-to-Sales 0.00
Price-to-Book 7.39
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.65
Resistance 3 (R3) 31.73 30.79 31.14
Resistance 2 (R2) 30.79 30.01 30.75 30.97
Resistance 1 (R1) 29.69 29.53 29.22 29.61 30.80
Pivot Point 28.75 28.75 28.52 28.71 28.75
Support 1 (S1) 27.65 27.97 27.18 27.57 26.38
Support 2 (S2) 26.71 27.49 26.67 26.21
Support 3 (S3) 25.61 26.71 26.04
Support 4 (S4) 25.53